GeneReach Biotechnology (4171) — Cash Flow Reinvestment Rate
GeneReach Biotechnology (4171) has a Cash Flow Reinvestment Rate of 3.73x as of December 2025, reinvesting NT$44.96 Million (capex NT$4.58 Million plus investments NT$40.39 Million) from operating cash flow of NT$12.05 Million. Check 4171 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GeneReach Biotechnology Cash Flow Reinvestment Rate (2018–2022)
Historical reinvestment intensity for GeneReach Biotechnology across 4 annual periods. Explore 4171 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for GeneReach Biotechnology (2018–2022)
Year-by-year capital reinvestment analysis for GeneReach Biotechnology. For live market cap and broader valuation context, see GeneReach Biotechnology (4171) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.26x | NT$92.92 Million | NT$357.63 Million | NT$44.90 Million | ▲ +361.7% |
| 2021 | 0.06x | NT$19.64 Million | NT$348.99 Million | NT$15.79 Million | ▼ -86.1% |
| 2020 | 0.40x | NT$68.72 Million | NT$169.82 Million | NT$64.87 Million | ▼ -62.3% |
| 2018 | 1.07x | NT$6.16 Million | NT$5.74 Million | NT$2.31 Million | — |